SO SOLV Solventum Loading... : Bullish and Bearish Analyst Opinions

Solventum is trading at a 7-8 PE (vs peers at 25+ PE) after paying down high-interest debt and authorizing a $1B buyback supported by ~$1B in normalized FCF. The stock price is temporarily depressed due to "index churn" and forced selling by 3M's dividend investors, creating a mispricing before healthcare funds step in and one-time spinoff costs fade. Go long on SOLV as an undervalued, relatively safe turnaround play with growth potential in AI medical billing. ERP migration issues causing supply chain disruptions, tariff impacts, and strict 2027 rebranding deadlines.